Jim Miller

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report, a monthly newsletter covering the contract drug development industry. A trial subscription can be obtained by calling 703.383.4903, by faxing 703.383.4905, by e-mailing info@pharmsource.com, or on the Web at www.pharmsource.com.

The sovereign debt crisis in the EU could greatly change the landscape for contract services.

Rising labor costs in China may result in increased competition for higher value services.

Rising labour rates in China may reduce its cost advantage, but will probably result in western suppliers facing more competition for higher value services.

The sovereign debt crisis in the EU could greatly change the landscape for contract services.

Having barely begun recovering from the economic slump that began in 2008, the contract services industry must now face the consequences of the debt crisis in Europe, which will include reduced bio/pharmaceutical expenditure by governments.

Eli Lilly faces up to the new realities of the bio/pharmaceutical industry through outsourcing.

Eli Lilly faces up to the new realities of the bio/pharmaceutical industry through outsourcing.

Lilly faces up to the new realities of the bio/pharmaceutical industry by embracing outsourcing.

CMOs' business model has all of the flaws of the captive model it is meant to replace.